Mineralys Therapeutics (MLYS) Current Assets (2022 - 2026)

Mineralys Therapeutics has disclosed Current Assets across 5 years of filings, most recently posting $652.5 million for Q1 2026.

• Current Assets for Q1 2026 came in at $652.5 million, up 84.05% year-over-year; the trailing twelve-month figure through Mar 2026 was $652.5 million (up 84.05% YoY), and the FY2025 annual result was $661.4 million, up 222.08% from the prior year.
• Current Assets came in at $652.5 million for Q1 2026 at Mineralys Therapeutics, down from $661.4 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $661.4 million in Q4 2025 to a low of $112.8 million in Q4 2022.
• The 5-year median for Current Assets is $296.6 million (2023), against an average of $351.0 million.
• Across the five-year window, Current Assets decreased 17.56% in 2024 and jumped 222.08% in 2025, its largest moves.
• Mineralys Therapeutics' Current Assets stood at $112.8 million in 2022, then soared by 120.81% to $249.1 million in 2023, then decreased by 17.56% to $205.4 million in 2024, then surged by 222.08% to $661.4 million in 2025, then retreated by 1.35% to $652.5 million in 2026.
• The last three Current Assets figures came in at $652.5 million (Q1 2026), $661.4 million (Q4 2025), and $599.8 million (Q3 2025), per Business Quant data.